Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

A CareSouth Carolina patient is among the first in the United States to receive a groundbreaking treatment aimed at slowing ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Eli Lilly and Company (LLY), one of the world’s largest pharmaceutical companies, boasts a diversified product profile. Lilly has consistently reported strong revenues and profits. It has seen ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Eli Lilly said it will spend $1.8 billion to boost production in Ireland of its popular diabetes and weight-loss drugs, along with ingredients for its recently approved Alzheimer’s treatment, Kisunla.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years.